Welcome to our dedicated page for Nephros news (Ticker: NEPH), a resource for investors and traders seeking the latest updates and insights on Nephros stock.
Nephros Inc. reports developments in water technology for medical and commercial markets, with emphasis on point-of-use filtration, waterborne pathogen risk reduction, and water management support. Company news commonly covers quarterly financial results, programmatic revenue trends, service offerings, customer education, and product adoption across healthcare facilities and other complex buildings.
Updates also include expansions of Nephros' water safety capabilities, regional market initiatives, and the Nephros Water Institute, an education effort focused on water quality, infection prevention, regulatory readiness, and emergency preparedness for compromised water events.
Nephros, Inc. (Nasdaq: NEPH) announced its participation in the 6th Annual MicroCap Leadership Summit on September 24, 2021. The virtual event, hosted by MicroCapClub, gathers over 100 investors worldwide. CEO Andy Astor will present on behalf of Nephros, which was selected as one of ten companies to showcase its innovative water filtration and pathogen detection solutions. This summit aims to connect experienced microcap investors and foster quality discussions on stock ideas.
Nephros, Inc. (Nasdaq: NEPH) has appointed Wes Lobo as Chief Commercial Officer, expanding his role from Chief Marketing Officer, which he held since February 2021. In his new position, Lobo will oversee all commercial strategies and operations, including sales, marketing, and product management. CEO Andy Astor emphasized the need for a cohesive commercial organization to meet customer needs effectively. Lobo expressed excitement for his new role and the growth potential at Nephros, underscoring the company's commitment to water quality solutions.
Nephros reported a 44% increase in net revenue for Q2 2021, totaling $2.3 million, driven by strong performance in their water filtration segment. The company achieved a 35% reduction in net loss, improving to $1.1 million, and an adjusted EBITDA improvement of 46%. The acquisition of GenArraytion, Inc. is expected to enhance capabilities in PCR testing. Additionally, the company submitted their HDF Assist Module for FDA 510(k) clearance, with potential for limited commercial launch later this year.
Nephros (Nasdaq: NEPH) has acquired the assets of GenArraytion, Inc., a leader in infectious disease monitoring. This acquisition aims to enhance Nephros's capabilities in pathogen detection, leveraging GenArraytion’s Polymerase Chain Reaction (PCR) technology to advance their pathogen detection systems. Nephros expects this strategic move to solidify its position in the emerging PCR testing market, improve water safety measures, and provide quicker testing solutions for waterborne pathogens. The integration of technologies is anticipated to enhance customer service through accurate and actionable data.
Nephros, Inc. (NASDAQ: NEPH), a leading water technology company, announced its participation in the Access to Giving Virtual Investor Conference from July 13-15, 2021. CEO Andy Astor will present on July 13th at 2:30 PM ET, with a replay available post-event. The conference will feature over 50 companies focusing on investor education and financial literacy. Nephros aims to advance water safety through innovative solutions. For more details, visit their official site or register for the conference.
Nephros, Inc. (Nasdaq: NEPH) reported an anticipated net revenue of approximately $2.2 million for Q2 2021, marking over a 40% year-over-year increase. Year-to-date revenue exceeded $5 million, reflecting a 20% increase compared to the same period in 2020 and 2019. The company also submitted its HDF Assist Module for FDA 510(k) clearance and noted growing revenue in its Pathogen Detection Systems business segment. Nephros ended Q2 with around $8.3 million in cash, positioning itself well for the upcoming months.
Nephros, Inc. (Nasdaq: NEPH) reported its highest first-quarter revenue of $2.7 million, an increase of 8% compared to the same period last year. The net loss improved by 55% to $0.5 million, while adjusted EBITDA showed a 13% improvement, totaling ($0.7 million). The company attributes this growth to increased customer acquisition and recurring revenue, as healthcare facilities shift focus from COVID-19 to water management. Nephros had cash and equivalents of $8.2 million as of March 31, 2021, indicating a solid financial position.
Nephros, Inc. (Nasdaq: NEPH) announced it will release its first quarter financial results on May 6, 2021, after market close. A conference call is scheduled for the same day at 4:30 PM ET, allowing investors to engage with company executives. Participants can join by calling domestic number 1-844-808-7106 or international number 1-412-317-5285. A replay of the call will be available until May 13, 2021. Nephros specializes in water purification and pathogen detection, focusing on point-of-use water safety.
Nephros, Inc. (Nasdaq: NEPH) has reported a preliminary net revenue of $2.7 million for Q1 2021, marking a 17% increase from the previous quarter and an 8% rise compared to the same period in 2020. This achievement signifies the highest first-quarter revenue in the company's history and the third-highest quarterly revenue overall. The company ended the quarter with approximately $8.1 million in cash. Results are attributed to strong performance across filtration markets despite the pandemic, with expectations for further growth as vaccination progresses.
Nephros, a water technology company specializing in filtration and pathogen detection, announced that CEO Andy Astor will present at the Q1 Virtual Investor Summit from March 23-25, 2021. Nephros's presentation is scheduled for March 23 at 2:30 p.m. ET. Interested participants can register for the event and request one-on-one meetings via the conference's website. Nephros is dedicated to advancing water safety in medical and commercial markets by providing innovative solutions.